{"id":16595,"date":"2022-05-05T18:12:38","date_gmt":"2022-05-05T16:12:38","guid":{"rendered":"https:\/\/neurologiaclinica.es\/clinical-trials\/"},"modified":"2025-04-16T11:03:20","modified_gmt":"2025-04-16T09:03:20","slug":"clinical-trials","status":"publish","type":"page","link":"https:\/\/neurologiaclinica.es\/en\/clinical-trials\/","title":{"rendered":"Clinical Trials"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"16595\" class=\"elementor elementor-16595 elementor-656\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-7b77917c elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"7b77917c\" data-element_type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-no\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-39b4485b\" data-id=\"39b4485b\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-5ce7aeb8 elementor-widget elementor-widget-heading\" data-id=\"5ce7aeb8\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Clinical Trials<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-ec88dcf elementor-reverse-tablet elementor-reverse-mobile elementor-section-content-middle elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"ec88dcf\" data-element_type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-no\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-7aa9e10\" data-id=\"7aa9e10\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e4ab929 elementor-widget elementor-widget-image\" data-id=\"e4ab929\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"500\" height=\"476\" src=\"https:\/\/neurologiaclinica.es\/wp-content\/uploads\/wULI-941-0028.jpg\" class=\"attachment-large size-large wp-image-16494\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-b627b65\" data-id=\"b627b65\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-71f643d elementor-widget elementor-widget-heading\" data-id=\"71f643d\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-heading-title elementor-size-default\">The Neurology Department of the Ruber Internacional Hospital in Madrid has an area dedicated to clinical trials.<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-71a476f elementor-widget elementor-widget-text-editor\" data-id=\"71a476f\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>In continuous collaboration with laboratories and associations, it offers its patients the possibility, if they meet the inclusion criteria, to participate in studies and trials of innovative drugs.<\/p><p>We have a long experience in performing this type of studies aimed at patients with different neurological pathologies and regardless of their place of residence.  <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-cf118c4 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"cf118c4\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-1e9375c\" data-id=\"1e9375c\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e607e96 elementor-search-form--skin-classic elementor-search-form--button-type-icon elementor-search-form--icon-search elementor-widget elementor-widget-search-form\" data-id=\"e607e96\" data-element_type=\"widget\" data-settings=\"{&quot;skin&quot;:&quot;classic&quot;}\" data-widget_type=\"search-form.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<search role=\"search\">\n\t\t\t<form class=\"elementor-search-form\" action=\"https:\/\/neurologiaclinica.es\/en\/\" method=\"get\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"elementor-search-form__container\">\n\t\t\t\t\t<label class=\"elementor-screen-only\" for=\"elementor-search-form-e607e96\">Search<\/label>\n\n\t\t\t\t\t\n\t\t\t\t\t<input id=\"elementor-search-form-e607e96\" placeholder=\"Search...\" class=\"elementor-search-form__input\" type=\"search\" name=\"s\" value=\"\">\n\t\t\t\t\t<input type='hidden' name='lang' value='en' \/>\n\t\t\t\t\t\t\t\t\t\t\t<button class=\"elementor-search-form__submit\" type=\"submit\" aria-label=\"Search\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"fas fa-search\"><\/i>\t\t\t\t\t\t\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/form>\n\t\t<\/search>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-33bcede elementor-widget elementor-widget-accordion\" data-id=\"33bcede\" data-element_type=\"widget\" data-widget_type=\"accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-accordion\">\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-5421\" class=\"elementor-tab-title\" data-tab=\"1\" role=\"button\" aria-controls=\"elementor-tab-content-5421\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-plus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">TRIALS FOR PATIENTS WITH EPILEPSY WITH OPEN ENROLLMENT<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-5421\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"region\" aria-labelledby=\"elementor-tab-title-5421\"><p><strong><u>UCB EP0162:<\/u><\/strong><strong>   <\/strong>A double-blind outpatient study to investigate the efficacy and safety of a single administration of Staccato alprazolam in study participants \u226512 years of age with stereotypical prolonged seizures . Alprazolam <\/p>\n<p><strong><em>Double-blind outpatient study to investigate the efficacy and safety of a single administration of Staccato alprazolam in study participants \u226512 years of age with prolonged stereotyped seizures  <\/em><\/strong><\/p>\n<p><strong>Criteria<\/strong><\/p>\n<ul>\n<li><em>Patients 12 years of age or older<\/em><\/li>\n<li><em>With a diagnosis of focal and\/or generalized epilepsy and seizures of prolonged duration.<\/em><\/li>\n<li><em>4 or more prolonged crises in the last 6 months<\/em><\/li>\n<\/ul>\n<p>Principal Investigator DR GIL-NAGEL<\/p>\n<\/p>\n<p><strong><u>UCB EP0165:<\/u><\/strong><strong>    <\/strong>An open-label outpatient extension study to evaluate the safety and tolerability of Staccato alprazolam in study participants \u226512 years of age with stereotypical prolonged seizures<strong>   <\/strong>Alprazolam<\/p>\n<p><strong><em>Open-label outpatient extension study to evaluate the safety and tolerability of alprazolam in patients with stereotypic prolonged seizures in study participants aged 12 years and older.<\/em><\/strong><\/p>\n<p><strong>Criteria<\/strong><\/p>\n<ul>\n<li><em>Patients who have previously participated in the EP0162 study.<\/em><\/li>\n<\/ul>\n<p>Principal Investigator DR GIL-NAGEL<\/p>\n<\/p>\n<p><strong><u>PRAX-562-221:<\/u><\/strong><strong>  <\/strong>A Phase 2, Double-Blind, Randomized Clinical trial to Explore the Tolerability, Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants with Developmental and epileptic Encephalopathies Followed by an Open-Label Extension.<\/p>\n<p>PRAX-562<\/p>\n<p><strong><em>Randomized, double-blind, Phase 2 clinical trial to explore the tolerability, efficacy and pharmacokinetics of PRAX-562 in pediatric participants with epileptic and developmental encephalopathies followed by open-label extension.  <\/em><\/strong><\/p>\n<p><strong>Cristerios<\/strong><\/p>\n<ul>\n<li><em>Patients between 2 and 18 years of age (included).<\/em><\/li>\n<li><em>Body weight over 10 kilos.<\/em><\/li>\n<li><em>With SCN2A mutation (and seizure onset in the first 3 months of life) or SCN8A mutation (and seizure onset in the first 6 months of life).<\/em><\/li>\n<li><em>At least 8 countable seizures per month.<\/em><strong><em> <\/em><\/strong><\/li>\n<\/ul>\n<p>Principal Investigator DR GIL-NAGEL<\/p>\n<\/p>\n<p><strong><u>NE001:<\/u><\/strong> SAFETY AND THERAPEUTIC MEASURES OF TRANSCRANIAL CATHODAL DIRECT CURRENT STIMULATION (TDCS) IN PATIENTS WITH REFRACTORY FOCAL EPILEPSY.<\/p>\n<p><strong><em>SAFETY AND THERAPEUTIC MEASURES OF CATHODAL TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS) IN PATIENTS WITH REFRACTORY FOCAL EPILEPSY<\/em><\/strong><\/p>\n<p><strong>Criteria:<\/strong><\/p>\n<ul>\n<li><em>Patients over 9 years of age<\/em><\/li>\n<li><em>Diagnosis of Focal Epilepsy<\/em><\/li>\n<li><em>At least 3 crises per month during the last year.<\/em><\/li>\n<\/ul>\n<p>  Principal Investigator DR GIL-NAGEL<\/p>\n<\/p>\n<p><strong><u>YKP509C003:<\/u><\/strong> Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of carisbamate (YKP509) as an add-on treatment for seizures associated with Lennox-Gastaut syndrome in children and adults, with optional open-label extension. Carisbamate. <\/p>\n<p><strong>Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of carisbamate (YKP509) as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in children and adults, with optional open-label extension.<\/strong><\/p>\n<p><strong>Criteria:<\/strong><\/p>\n<ul>\n<li><em>Patients between 4 and 55 years old (included).<\/em><\/li>\n<li><em>Diagnosed with Lennox-Gastaut Syndrome.<\/em><\/li>\n<li><em>8 or more Countable Epileptic Seizures with drop ( Tonic, Atonic or GTC ) in the 4 weeks prior to BSL<\/em><\/li>\n<li><em>1-4 Antiepileptic drugs at a stable dose during the 4 weeks prior to the baseline visit.<\/em><\/li>\n<\/ul>\n<p>  Principal Investigator DR GIL-NAGEL<\/p>\n<\/p>\n<p><strong><u>XPF-010-301:<\/u><\/strong> A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizure XEN1101.<\/p>\n<p><strong><em>Randomized, double-blind, placebo-controlled, multicenter phase 3 study to evaluate the safety, tolerability and efficacy of XEN1101 as adjunctive therapy in focal onset seizures.<\/em><\/strong><\/p>\n<p><strong><em>Criteria:<\/em><\/strong><\/p>\n<ul>\n<li><em>Patients 18 years of age or older.  <\/em><\/li>\n<li><em>With diagnosis of Focal Epilepsy.<\/em><\/li>\n<li><em>With stable doses of 1-3 antiepileptic drugs 4 weeks prior to the baseline visit.<\/em><em style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"> <\/em><\/li>\n<\/ul>\n<p>  Principal Investigator DR GIL-NAGEL<\/p>\n<\/p>\n<p><strong><u>XPF-010-304<\/u><\/strong><strong><u>:<\/u><\/strong> A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Adults Diagnosed With Epilepsy. XEN1101 <\/p>\n<p><strong>Multicenter, open-label, long-term study of safety, tolerability and efficacy of XEN1101 in adults diagnosed with epilepsy.<\/strong><\/p>\n<p><strong><em>Criteria:<\/em><\/strong><\/p>\n<ul>\n<li><em>Patients who have previously participated in the XPF-010-301 study.<\/em><em style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"> <\/em><\/li>\n<\/ul>\n<p>  Principal Investigator DR GIL-NAGEL<\/p>\n<\/p>\n<p><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"><u>EstuEla2022 <\/u><\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"><u>:<\/u><\/strong> <strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"><u> <\/u><\/strong><span style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\">Treatment of refractory epilepsy associated with tuberous sclerosis complex (TSC) with full-spectrum cannabis extract: SPECTRUM&#8221;. Cannabis Extract <\/span><\/p>\n<p><strong>  Treatment, with full spectrum cannabis extract, of refractory epilepsy associated with complex Tuberous Sclerosis (TSC): SPECTRUM&#8221;.<\/strong><\/p>\n<p><strong> <\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"><em>Criteria:<\/em><\/strong><\/p>\n<ul>\n<li><em>Patients between 2 and 65 years of age (included).<\/em><\/li>\n<li><em>Diagnosed with epilepsy associated with Tuberous Sclerosis Complexes .<\/em><\/li>\n<li><em>4 or more Epileptic Seizures per month.<\/em><\/li>\n<li><em>On treatment with 1-3 Antiepileptic Drugs at stable doses 4 weeks prior to the Baseline Visit.<\/em><em style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"> <\/em><\/li>\n<\/ul>\n<p>  Principal Investigator DR GIL-NAGEL<\/p>\n<\/p>\n<p><strong> <\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"><u>GWEP17005 <\/u><\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"><u>:<\/u><\/strong> <strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"><u> <\/u><\/strong><span style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\">An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Participants with Tuberous Sclerosis Complex (Age 1 Month to &lt; 2 Years of Age), Dravet Syndrome (1 Year to &lt; 2 Years of Age), or Lennox-Gastaut Syndrome (1 Year to &lt; 2 Years of Age) who Experience Inadequately-controlled Seizures Cannabidiol<\/span><\/p>\n<p><strong> <\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"><em>Single-arm, open-label study to evaluate the safety, pharmacokinetics, and efficacy of adjuvant cannabidiol oral solution (GWP42003-P) in participants with tuberous sclerosis complex (1 month to &lt; 2 years of age), Dravet syndrome (1 year to &lt; 2 years of age), or Lennox-Gastaut syndrome (1 year to &lt; 2 years of age) experiencing inadequately controlled seizures<\/em><\/strong><\/p>\n<p><strong><em>Criteria:  <\/em><\/strong><\/p>\n<ul>\n<li><em>Patients with Dravet Syndrome and age between 1 and 2 years old.<\/em><\/li>\n<li><em>Patients with Lennox-Gastaut syndrome aged between 1 and 2 years.<\/em><\/li>\n<li><em>Patients with CSD and age between 1 month and 2 years.<\/em><\/li>\n<li><em>On treatment with 1 or more stable antiepileptic drugs 2 weeks prior to Visit 3<\/em><\/li>\n<\/ul>\n<p>  Principal Investigator DR GIL-NAGEL<\/p>\n<\/p>\n<p><strong><u>EXPAND:<\/u><\/strong> Deep phenotyping of non-epileptic phenomena in adult patients with Dravet Syndrome . Observational <\/p>\n<p><strong><em>Deep phenotyping of non-epileptic phenomena in adult patients with Dravet syndrome.<\/em><\/strong><\/p>\n<p><strong><em> <\/em><\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"><em>Criteria:<\/em><\/strong><\/p>\n<p><strong><em> <\/em><\/strong><em style=\"background-color: transparent; color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif;\">Patients diagnosed with Dravet Syndrome over 18 years of age.<\/em><\/p>\n<p><em> <\/em><span style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\">Principal Investigators DR BELTR\u00c1N \/ DR GIL-NAGEL<\/span><\/p>\n<\/p>\n<p><strong><u>eDREXCO:<\/u><\/strong><strong>  <\/strong>Efficient drugs in Dravet syndrome for Executive and Cognitive Outcomes (eDREXCO). Observational <\/p>\n<p><strong><em>Effective drugs in Dravet syndrome for executive and cognitive outcomes<\/em><\/strong><\/p>\n<p><strong><em>Criteria:<\/em><\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"><em> <\/em><\/strong><\/p>\n<ul>\n<li><em>Patients older than 2 years.<\/em><\/li>\n<li><em>Diagnosed with Dravet syndrome with confirmation of mutation in the SCN1A gene.<\/em><\/li>\n<li><em>Who has received in the past treatment with any of the following drugs: Fenfluramine, Styripentol, Valproic, Cannabidiol, Topiramate or Clobazam.<\/em><\/li>\n<\/ul>\n<p><em> <\/em><span style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\">Principal Investigators DR VALLS \/ DR GIL-NAGEL<\/span><\/p>\n<p><span style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"> <\/span><\/p>\n<p><strong>RAD-GRIN-201<\/strong><strong><u>:<\/u><\/strong><strong>  <\/strong>A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radiprodil in Patients with Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) Type II. Radiprodil <\/p>\n<p><strong><em><u>  <\/u><\/em><\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"><em>Multicenter, open-label study to assess the safety, tolerability, pharmacokinetics and effect on seizures and behavioral symptoms of radiprodil in patients with tuberous sclerosis complex (TSC) or focal cortical dysplasia (FCD) type II<\/em><\/strong><\/p>\n<p><strong><em>Criteria:<\/em><\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"><em> <\/em><\/strong><\/p>\n<ul>\n<li><em>Patients between 6 months and 18 years of age<\/em><\/li>\n<li><em>Diagnosed with Dysplasia type II (with confirmatory MRI).<\/em><\/li>\n<li><em>O Diagnosis of TSC (by clinical and \/ or Genetic confirmation)<\/em><\/li>\n<li><em>8 or more Countable Seizures in the 4 weeks prior to Visit 2<\/em><\/li>\n<li><em>And stable treatment in the 28 days prior to the Screening Visit (V1).<\/em><em style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"> <\/em><\/li>\n<\/ul>\n<p>Principal Investigators DR GIL-NAGEL<\/p>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-5422\" class=\"elementor-tab-title\" data-tab=\"2\" role=\"button\" aria-controls=\"elementor-tab-content-5422\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-plus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">TRIALS FOR PARKINSON'S PATIENTS WITH OPEN ENROLLMENT<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-5422\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"2\" role=\"region\" aria-labelledby=\"elementor-tab-title-5422\"><div class=\"vc_tta-panel-body\">\n<div class=\"wpb_text_column wpb_content_element \">\n<div class=\"wpb_wrapper\">\n<div class=\"vc_tta-panel-body\">\n<div class=\"wpb_text_column wpb_content_element \">\n<div class=\"wpb_wrapper\">\n<p><strong><u>dBM-DEV<\/u><\/strong> <strong><u>:<\/u><\/strong> Digital biomarkers development, validation and verification study.<\/p>\n<\/p>\n<p><strong>Study of development, validation and verification of digital biomarkers.<\/strong><\/p>\n<p><strong> <\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\">Criteria:<\/strong><\/p>\n<ul>\n<li>Over 18 years of age.<\/li>\n<li><em>Participant uses a compatible smart phone, a smart watch will be provided for the duration of the study.<\/em><\/li>\n<li><em>The participant has a caregiver with whom he shares his room at night.<\/em><\/li>\n<li><em>Known REM sleep behavior disorder as defined by the International Classification of Sleep Disorders (ICSD-3) as demonstrated by polysomnography with at least one episode per week (on average over the past month, frequency reported with caregiver assistance).<\/em><em style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"> <\/em><\/li>\n<\/ul>\n<p>Principal Investigator DRA KURTIS<\/p>\n<\/p>\n<p><strong><u>AI-PRA Study<\/u><\/strong> <strong><u>:<\/u><\/strong> Artificial intelligence-based Parkinson&#8217;s risk assessment study.<\/p>\n<\/p>\n<p><strong>Artificial intelligence-based Parkinson&#8217;s risk assessment study.<\/strong><\/p>\n<p><strong> <\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\">Criteria:<\/strong><\/p>\n<p><strong> <\/strong><span style=\"background-color: transparent; color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif;\">Over 55 years of age.<\/span><\/p>\n<ul>\n<li>At least one of these requirements:\n<ul>\n<li><em>Olfactory Loss ( measured with UPSIT )  <\/em><\/li>\n<li><em>REM Sleep Behavior Disorder (confirmed by polysomnography)<\/em><\/li>\n<li><em>Neurogenic Orthostatic Hypotension.<\/em><\/li>\n<\/ul>\n<\/li>\n<li><em>Participant uses a compatible smart phone (a smart watch will be provided for the duration of the study)<\/em><\/li>\n<\/ul>\n<p>Principal Investigator DRA KURTIS<\/p>\n<\/p>\n<p><strong><u>AI-PMP Study<\/u><\/strong><strong><u>:<\/u><\/strong> AI-based progression and medication response prediction study.<\/p>\n<\/p>\n<p><strong>AI-based study on prediction of progression and response to medication.<\/strong><\/p>\n<p><strong> <\/strong><strong>Criteria:<\/strong><\/p>\n<p><strong> <\/strong>Diagnosis of Parkinson&#8217;s disease according to the MDS criteria.<\/p>\n<ul>\n<li><em>Age between 40 and 80 years old (included).<\/em><\/li>\n<li><em>Participant uses a compatible smart phone (a smart watch will be provided for the duration of the study)<\/em><\/li>\n<li><em>Patients with atypical parkinsonian syndrome, more than 4 doses of L-Dopa per day (LEED greater than 1500 mg), hallucinations, Hoehn and Yahr greater than 3 in ON will not be included.<\/em><\/li>\n<\/ul>\n<p><em> <\/em>Principal Investigator DRA KURTIS<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d8c3562 elementor-widget elementor-widget-accordion\" data-id=\"d8c3562\" data-element_type=\"widget\" data-widget_type=\"accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-accordion\">\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-2271\" class=\"elementor-tab-title\" data-tab=\"1\" role=\"button\" aria-controls=\"elementor-tab-content-2271\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-plus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">TRIALS OPENING IN THE COMING MONTHS<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-2271\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"region\" aria-labelledby=\"elementor-tab-title-2271\"><h5 class=\"MsoNormal\" style=\"margin-bottom: 0cm; line-height: normal;\"><b><span style=\"mso-ascii-font-family: Calibri; mso-fareast-font-family: 'Times New Roman'; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri; color: #0070c0; mso-fareast-language: ES;\">EPILEPSY<\/span><\/b><\/h5>\n<p class=\"MsoNormal\" style=\"margin-bottom: 0cm; line-height: normal;\"><b><span style=\"mso-ascii-font-family: Calibri; mso-fareast-font-family: 'Times New Roman'; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri; color: #0070c0; mso-fareast-language: ES;\"> <\/span><\/b><\/p>\n<p><strong><u>NBI-921352-DEE2013<\/u><\/strong>A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).<\/p>\n<\/p>\n<p><strong><em>Prospective, long-term, interventional, active extension study to evaluate the safety and tolerability of NBI-921352 as adjuvant therapy in subjects with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).<\/em><\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"><em> <\/em><\/strong><\/p>\n<p><strong>Criteria:<\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"> <\/strong><\/p>\n<ul>\n<li><em>Patients between 12 and 21 years of age (both included) with a diagnosis of SCN8A-DEE.<\/em><\/li>\n<li><em>History or ongoing motor abnormalities (ataxia, hypotonia, dystonia&#8230;).<\/em><\/li>\n<li><em>History of convulsive or non-convulsive status.<\/em><\/li>\n<li><em>Beneficial response to sodium channel blockers (phenytoin, valproate, carbamazepine, lacosamide, lamotrigine, rufinamide and oxcarbamazepine).<\/em><\/li>\n<li><em>At least 4 countable motor epileptic seizures per month.<\/em><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"><em> <\/em><\/strong><\/li>\n<\/ul>\n<p>  Principal Investigator DR GIL-NAGEL<\/p>\n<\/p>\n<p><strong><u>BHV7000-303:<\/u><\/strong> A Phase 2\/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy BHV-7000.<\/p>\n<\/p>\n<p><strong><em>Multicenter, randomized, double-blind, placebo-controlled, phase 2\/3 study to evaluate the efficacy, safety and tolerability of BHV-7000 in subjects with refractory focal-onset epilepsy.<\/em><\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"><em> <\/em><\/strong><\/p>\n<p><strong>Criteria:<\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\">                <\/strong><\/p>\n<ul>\n<li><em>Patients between 18 and 75 years of age.<\/em><\/li>\n<li><em>4 or more observable focal seizures per month in the 3 months prior to screnning.<\/em><\/li>\n<li><em>1 to 3 antiepileptic drugs in stable dosage 1 month before the baseline visit.<\/em><em style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"> <\/em><\/li>\n<\/ul>\n<p>Principal Investigator DR BELTR\u00c1N<\/p>\n<\/p>\n<p><strong><u>BHV7000-201 :<\/u><\/strong> A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy. BHV-7000 <\/p>\n<\/p>\n<p><strong><em>Long-term, multicenter, global, Phase 2, multicenter safety study designed to evaluate the safety and tolerability of BHV-7000 in subjects with refractory focal epilepsy.<\/em><\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"><em> <\/em><\/strong><\/p>\n<p><strong>Criteria:<\/strong><em style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"> <\/em><\/p>\n<ul>\n<li><em>Patients who have previously participated in the BHV7000-303 study.<\/em><\/li>\n<\/ul>\n<p>Principal Investigator DR BELTR\u00c1N<\/p>\n<p><strong> <\/strong><\/p>\n<p><strong><u>EP0213 <\/u><\/strong><strong><u>:<\/u><\/strong> OPEN-LABEL, SINGLE-ARM, PHASE 3 STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF FENFLURAMINE (HYDROCHLORIDE) IN INFANTS 1 YEAR TO LESS THAN 2 YEARS OF AGE WITH DRAVET SYNDROME Fenfluramine.<\/p>\n<\/p>\n<p><strong>PHASE 3, OPEN-LABEL, SINGLE-ARM, PHASE 3 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF FENFLURAMINE (HYDROCHLORIDE) IN INFANTS 1 TO LESS THAN 2 YEARS OF AGE WITH DRAVET SYNDROME<\/strong><\/p>\n<p><strong> <\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\">Criteria:<\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"> <\/strong><\/p>\n<ul>\n<li><em>Patients aged 1-2 years.<\/em><\/li>\n<li><em>Diagnosed with Dravet Syndrome.<\/em><\/li>\n<li><em>On treatment with 1 or more antiepileptic drugs at a stable dose 4 weeks prior to the baseline visit.<\/em><\/li>\n<li><em>4 or more Countable Motor Crises per month.<\/em><\/li>\n<li><em>Body Weight 8 kilos or more.<\/em><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\">                <\/strong><\/li>\n<\/ul>\n<p>Principal Investigator DR GIL-NAGEL<\/p>\n<\/p>\n<\/p>\n<p><strong><u>LP352-301<\/u><\/strong> <strong><u>:<\/u><\/strong> A Phase 3 randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with Developmental and Epileptic Encephalopathies (DEE). LP352 <\/p>\n<\/p>\n<p><strong>A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy, safety and tolerability of LP352 in the treatment of seizures in children and adults with developmental and epileptic encephalopathies (DEE).<\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"> <\/strong><\/p>\n<p><strong>Criteria:<\/strong><strong style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"> <\/strong><\/p>\n<ul>\n<li>Patient with Epileptic and Developmental Encephalopathy (DEE).<\/li>\n<li><em>Aged between 2 and 65 years old (included).<\/em><\/li>\n<li><em>Body weight equal to or greater than 10 kilos.<\/em><\/li>\n<li><em>They must have Motor Epileptic Seizures.  <\/em><\/li>\n<li><em>At least 4 crises per month during the 3 months prior to the Initial Visit.<\/em><\/li>\n<li><em>Must take between 1-4 antiepileptic drugs at stable doses 4 weeks prior to the Initial Visit.<\/em><em style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"> <\/em><\/li>\n<\/ul>\n<p>Principal Investigator DR GIL-NAGEL<\/p>\n<\/p>\n<\/p>\n<p><strong><u>LP352-302<\/u><\/strong> <strong><u>:<\/u><\/strong> A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Dravet Syndrome LP352.<\/p>\n<\/p>\n<p><strong>Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy, safety and tolerability of LP352 in the treatment of seizures in children and adults with Dravet syndrome.<\/strong><\/p>\n<p><strong>Criteria:<\/strong><\/p>\n<p><strong> <\/strong>Patient diagnosed with Dravet Syndrome .<\/p>\n<ul>\n<li><em>Aged between 2 and 65 years old (included).<\/em><\/li>\n<li><em>Body weight equal to or greater than 10 kilos.<\/em><\/li>\n<li><em>They must have Motor Epileptic Seizures.  <\/em><\/li>\n<li><em>At least 4 crises per month during the 3 months prior to the Initial Visit.<\/em><\/li>\n<li><em>Must take between 1-4 antiepileptic drugs at stable doses 4 weeks prior to the Initial Visit.<\/em><\/li>\n<\/ul>\n<p><em> <\/em>Principal Investigator DR GIL-NAGEL<\/p>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-318b415 elementor-widget elementor-widget-accordion\" data-id=\"318b415\" data-element_type=\"widget\" data-widget_type=\"accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-accordion\">\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-5191\" class=\"elementor-tab-title\" data-tab=\"1\" role=\"button\" aria-controls=\"elementor-tab-content-5191\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-plus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">TRIALS FOR PATIENTS WITH EPILEPSY WITH CLOSED ENROLLMENT<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-5191\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"region\" aria-labelledby=\"elementor-tab-title-5191\"><p><strong><u>ZX008-1900<\/u><\/strong> An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients with Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome. Fenfluramine <\/p>\n<p>Principal Investigator DR GIL-NAGEL<\/p>\n<\/p>\n<p><strong><u>XPF-008-201<\/u><\/strong> A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, with an Open-label Extension ( Xenon Pharmaceuticals Inc. ). XEN1101 <\/p>\n<p>Principal Investigator DR GIL-NAGEL<\/p>\n<p><strong> <\/strong><\/p>\n<p><strong><u>NBI-827104-CSWS2025<\/u><\/strong> Long-Term, Open-Label Extension Study to Evaluate the Safety and Tolerability of NBI-827104 in Pediatric Subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep. NBI-827104 <\/p>\n<p>Principal Investigator DR GIL-NAGEL<\/p>\n<p><strong> <\/strong><\/p>\n<p><strong><u>TAK 935 18 001<\/u><\/strong> A phase 2, Prospective, International, open-label, ulti-site, extension study to Assess the long-Term safety and Tolerability of TAK-935 as adjunctive Therapy in Patients with rare Epilepsy. TAK-935 <\/p>\n<p>DR GIL-NAGEL<\/p>\n<p><strong> <\/strong><\/p>\n<p><strong><u>PTC743-MIT-001-EP<\/u><\/strong> Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects with Refractory Epilepsy. Vatiquinone <\/p>\n<p>Principal Investigator DR GIL-NAGEL<\/p>\n<\/p>\n<p><strong><u>CANDID 1263 (Lou Lou)<\/u><\/strong><strong>    <\/strong>Endpoint Enabling Study in Cyclin-dependent kinase-like 5 Deficiency Disorder (CDD) . CDKL5 Deficiency Disorder (CDD).   <\/p>\n<p>Principal Investigator DR GIL-NAGEL<\/p>\n<p><strong> <\/strong><\/p>\n<p><strong><u>FENDEEP<\/u><\/strong>Fenfluramine for the treatment of different types of developmental and epileptic encephalopathies: a pilot trial exploring epileptic and non-epileptic outcomes. Fenfluramine <\/p>\n<p>Principal Investigator DR GIL-NAGEL<\/p>\n<\/p>\n<p><strong><u>1042-TSC-3001 BIORASI<\/u><\/strong> A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC), Ganaxolone<\/p>\n<p>Principal Investigator Dr GIL-NAGEL<\/p>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-5192\" class=\"elementor-tab-title\" data-tab=\"2\" role=\"button\" aria-controls=\"elementor-tab-content-5192\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-plus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">TRIALS FOR ALZHEIMER'S PATIENTS - RECRUITMENT CLOSED<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-5192\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"2\" role=\"region\" aria-labelledby=\"elementor-tab-title-5192\"><p><strong><u>PD0053<\/u><\/strong> A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY PARKINSON&#8217;S DISEASE UCB0599<\/p>\n<p><strong> <\/strong><span style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\">Principal Investigator Dr. M\u00d3NICA KURTIS<\/span><\/p>\n<p><span style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"> <\/span><\/p>\n<\/p>\n<p><strong><u>BIA 28-6156-201<\/u><\/strong><strong><u>: <\/u><\/strong>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson&#8217;s Disease With a Pathogenic Variant in the Glucocerebrosidase<em>(GBA1<\/em>) BIA 28-6156.<\/p>\n<p>Principal Investigator Dr. M\u00d3NICA KURTIS<\/p>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<div id=\"elementor-tab-title-5193\" class=\"elementor-tab-title\" data-tab=\"3\" role=\"button\" aria-controls=\"elementor-tab-content-5193\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-left\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"fas fa-plus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">TRIALS FOR PARKINSON'S PATIENTS - RECRUITMENT CLOSED<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-5193\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"3\" role=\"region\" aria-labelledby=\"elementor-tab-title-5193\"><p><strong><u>PD0053<\/u><\/strong> A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY PARKINSON&#8217;S DISEASE UCB0599<\/p>\n<p><strong> <\/strong><span style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\">Principal Investigator Dr. M\u00d3NICA KURTIS<\/span><\/p>\n<p><span style=\"color: var( --e-global-color-cf4575c ); font-family: var( --e-global-typography-text-font-family ), Sans-serif; font-size: var( --e-global-typography-text-font-size );\"> <\/span><\/p>\n<\/p>\n<p><strong><u>BIA 28-6156-201<\/u><\/strong><strong><u>: <\/u><\/strong>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson&#8217;s Disease With a Pathogenic Variant in the Glucocerebrosidase<em>(GBA1<\/em>) BIA 28-6156.<\/p>\n<p>Principal Investigator Dr. M\u00d3NICA KURTIS<\/p>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6843e8d elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"6843e8d\" data-element_type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-563f468 elementor-widget elementor-widget-text-editor\" data-id=\"563f468\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>If you are interested in receiving information please contact us.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cc8426e elementor-button-align-stretch elementor-widget elementor-widget-form\" data-id=\"cc8426e\" data-element_type=\"widget\" data-settings=\"{&quot;step_next_label&quot;:&quot;Next&quot;,&quot;step_previous_label&quot;:&quot;Previous&quot;,&quot;button_width&quot;:&quot;100&quot;,&quot;step_type&quot;:&quot;number_text&quot;,&quot;step_icon_shape&quot;:&quot;circle&quot;}\" data-widget_type=\"form.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<form class=\"elementor-form\" method=\"post\" name=\"New form\">\n\t\t\t<input type=\"hidden\" name=\"post_id\" value=\"16595\"\/>\n\t\t\t<input type=\"hidden\" name=\"form_id\" value=\"cc8426e\"\/>\n\t\t\t<input type=\"hidden\" name=\"referer_title\" value=\"\" \/>\n\n\t\t\t\n\t\t\t<div class=\"elementor-form-fields-wrapper elementor-labels-above\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-field-type-text elementor-field-group elementor-column elementor-field-group-name elementor-col-100 elementor-field-required\">\n\t\t\t\t\t\t\t\t\t\t\t\t<label for=\"form-field-name\" class=\"elementor-field-label\">\n\t\t\t\t\t\t\t\tName  \t\t\t\t\t\t\t<\/label>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<input size=\"1\" type=\"text\" name=\"form_fields[name]\" id=\"form-field-name\" class=\"elementor-field elementor-size-sm  elementor-field-textual\" placeholder=\"Name\" required=\"required\">\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<div class=\"elementor-field-type-email elementor-field-group elementor-column elementor-field-group-email elementor-col-100 elementor-field-required\">\n\t\t\t\t\t\t\t\t\t\t\t\t<label for=\"form-field-email\" class=\"elementor-field-label\">\n\t\t\t\t\t\t\t\tE-mail address\t\t\t\t\t\t\t<\/label>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<input size=\"1\" type=\"email\" name=\"form_fields[email]\" id=\"form-field-email\" class=\"elementor-field elementor-size-sm  elementor-field-textual\" placeholder=\"E-mail address\" required=\"required\">\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<div class=\"elementor-field-type-email elementor-field-group elementor-column elementor-field-group-field_6cc6dfc elementor-col-100 elementor-field-required\">\n\t\t\t\t\t\t\t\t\t\t\t\t<label for=\"form-field-field_6cc6dfc\" class=\"elementor-field-label\">\n\t\t\t\t\t\t\t\tPhone\t\t\t\t\t\t\t<\/label>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<input size=\"1\" type=\"email\" name=\"form_fields[field_6cc6dfc]\" id=\"form-field-field_6cc6dfc\" class=\"elementor-field elementor-size-sm  elementor-field-textual\" placeholder=\"phone\" required=\"required\">\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<div class=\"elementor-field-type-select elementor-field-group elementor-column elementor-field-group-field_75e1bd8 elementor-col-100 elementor-field-required\">\n\t\t\t\t\t\t\t\t\t\t\t\t<label for=\"form-field-field_75e1bd8\" class=\"elementor-field-label\">\n\t\t\t\t\t\t\t\tAny particular pathology\t\t\t\t\t\t\t<\/label>\n\t\t\t\t\t\t\t\t<div class=\"elementor-field elementor-select-wrapper remove-before \">\n\t\t\t<div class=\"select-caret-down-wrapper\">\n\t\t\t\t<i aria-hidden=\"true\" class=\"eicon-caret-down\"><\/i>\t\t\t<\/div>\n\t\t\t<select name=\"form_fields[field_75e1bd8]\" id=\"form-field-field_75e1bd8\" class=\"elementor-field-textual elementor-size-sm\" required=\"required\">\n\t\t\t\t\t\t\t\t\t<option value=\"Epilepsy\">Epilepsy<\/option>\n\t\t\t\t\t\t\t\t\t<option value=\"Parkinson&#039;s\">Parkinson&#039;s<\/option>\n\t\t\t\t\t\t\t\t\t<option value=\"Alzheimer&#039;s disease\">Alzheimer&#039;s disease<\/option>\n\t\t\t\t\t\t\t<\/select>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<div class=\"elementor-field-type-textarea elementor-field-group elementor-column elementor-field-group-field_a221377 elementor-col-100 elementor-field-required\">\n\t\t\t\t\t\t\t\t\t\t\t\t<label for=\"form-field-field_a221377\" class=\"elementor-field-label\">\n\t\t\t\t\t\t\t\tAre you interested in a particular trial?\t\t\t\t\t\t\t<\/label>\n\t\t\t\t\t\t<textarea class=\"elementor-field-textual elementor-field  elementor-size-sm\" name=\"form_fields[field_a221377]\" id=\"form-field-field_a221377\" rows=\"4\" placeholder=\"text\" required=\"required\"><\/textarea>\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<div class=\"elementor-field-type-textarea elementor-field-group elementor-column elementor-field-group-message elementor-col-100\">\n\t\t\t\t\t\t\t\t\t\t\t\t<label for=\"form-field-message\" class=\"elementor-field-label\">\n\t\t\t\t\t\t\t\tMessage\t\t\t\t\t\t\t<\/label>\n\t\t\t\t\t\t<textarea class=\"elementor-field-textual elementor-field  elementor-size-sm\" name=\"form_fields[message]\" id=\"form-field-message\" rows=\"4\" placeholder=\"Message\"><\/textarea>\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<div class=\"elementor-field-group elementor-column elementor-field-type-submit elementor-col-100 e-form__buttons\">\n\t\t\t\t\t<button class=\"elementor-button elementor-size-sm\" type=\"submit\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Send to<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/button>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/form>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-d634d7c elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"d634d7c\" data-element_type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-no\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-6b96b66\" data-id=\"6b96b66\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-73185d4 elementor-widget elementor-widget-heading\" data-id=\"73185d4\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">GET INFO<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4e29b36 elementor-align-center elementor-widget elementor-widget-button\" data-id=\"4e29b36\" data-element_type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-lg\" href=\"https:\/\/www.neurologiaclinica.es\/neurologos-en-madrid\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">About our Units and Treatments<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>The Neurology Department of the Ruber Internacional Hospital in Madrid has an area dedicated to clinical trials. In continuous collaboration with laboratories and associations, it offers its patients the possibility, if they meet the inclusion criteria, to participate in studies and trials of innovative drugs. We have a long experience in performing this type of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":16081,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-16595","page","type-page","status-publish","has-post-thumbnail","hentry"],"rankMath":{"parentDomain":"neurologiaclinica.es","noFollowDomains":[],"noFollowExcludeDomains":[],"noFollowExternalLinks":false,"featuredImageNotice":"The featured image should be at least 200 by 200 pixels to be picked up by Facebook and other social media sites.","pluginReviewed":true,"postSettings":{"linkSuggestions":true,"useFocusKeyword":false},"frontEndScore":false,"postName":"clinical-trials","permalinkFormat":"https:\/\/neurologiaclinica.es\/en\/%pagename%\/","showLockModifiedDate":true,"assessor":{"focusKeywordLink":"https:\/\/neurologiaclinica.es\/wp-admin\/edit.php?focus_keyword=%focus_keyword%&post_type=%post_type%","hasTOCPlugin":true,"primaryTaxonomy":false,"serpData":{"title":"Clinical Trials. Neurology Service ","description":"The Neurology Department of the Ruber Internacional Hospital in Madrid has an Area dedicated to clinical trials.","focusKeywords":"clinical trials","pillarContent":false,"canonicalUrl":"","breadcrumbTitle":"","advancedRobots":[],"facebookTitle":"","facebookDescription":"","facebookImage":"","facebookImageID":"","facebookHasOverlay":false,"facebookImageOverlay":"","facebookAuthor":"","twitterCardType":"","twitterUseFacebook":true,"twitterTitle":"","twitterDescription":"","twitterImage":"","twitterImageID":"","twitterHasOverlay":false,"twitterImageOverlay":"","twitterPlayerUrl":"","twitterPlayerSize":"","twitterPlayerStream":"","twitterPlayerStreamCtype":"","twitterAppDescription":"","twitterAppIphoneName":"","twitterAppIphoneID":"","twitterAppIphoneUrl":"","twitterAppIpadName":"","twitterAppIpadID":"","twitterAppIpadUrl":"","twitterAppGoogleplayName":"","twitterAppGoogleplayID":"","twitterAppGoogleplayUrl":"","twitterAppCountry":"","robots":{"index":true},"twitterAuthor":"username","primaryTerm":0,"authorName":"administrador","titleTemplate":"%title% %page% %sep% %sitename%","descriptionTemplate":"","showScoreFrontend":true,"lockModifiedDate":false},"powerWords":["a cut above","absolute","absolutely","absolutely lowest","absurd","abuse","accurate","accuse","achieve","actionable","adaptable","adequate","admit","adorable","advantage","advice","affordable","aggravate","aggressive","agitated","agonizing","agony","alarmed","alarming","alienated","aligned","alive","all-inclusive","alluring","always","amazing","amp","animated","annihilate","announcing","anonymous","antagonistic","anxious","apocalypse","appalled","approved","approving","argumentative","armageddon","arrogant","ass kicking","assault","assured","astonishing","astounded","astounding","at ease","atrocious","attack","attractive","audacity","authentic","authoritative","authority","avoid","aware","awe-inspiring","awesome","awkward","backbone","backdoor","backed","backlash","backstabbing","badass","balanced","banned","bargain","barrage","basic","battle","beaming","beat down","beating","beautiful","beauty","begging","behind the scenes","belief","belong","best","best-selling","better","beware","big","billion","black market","blacklisted","blast","blessed","blinded","blissful","blood","bloodbath","bloodcurdling","bloody","blunder","blushing","bold","bomb","bona","bona fide","bonanza","bonus","bootleg","bottom line","bountiful","brave","bravery","brazen","break","breaking","breakthrough","breathtaking","bright","brilliant","broke","brutal","budget","buffoon","bullshit","bully","bumbling","buy","cadaver","calm","cancel anytime","capable","captivate","captivating","carefree","case study","cash","cataclysmic","catapult","catastrophe","caution","censored","centered","certain","certainly","certified","challenge","charming","cheap","cheat","cheat-sheet","cheer","cheerful","child-like","clarity","classified","clear","clueless","collapse","colorful","colossal","comfortable","compare","competitive","complete","completely","completeness","comprehensive","compromise","compulsive","concealed","conclusive","condemning","condescending","confess","confession","confessions","confident","confidential","conquer","conscientious","constructive","content","contrary","controlling","controversial","convenient","convert","cool","cooperative","copy","corpse","corrupt","corrupting","courage","courageous","cover-up","covert","coward","cowardly","crammed","crave","crazy","create","creative","cringeworthy","cripple","crisis","critical","crooked","crush","crushing","damaging","danger","dangerous","daring","dazzling","dead","deadline","deadly","death","decadent","deceived","deceptive","deep","defiance","definitely","definitive","defying","dejected","delicious","delight","delighted","delightful","delirious","delivered","demoralizing","deplorable","depraved","desire","desperate","despicable","destiny","destroy","detailed","devastating","devoted","diagnosed","direct","dirty","disadvantages","disastrous","discount","discover","disdainful","disempowered","disgusted","disgusting","dishonest","disillusioned","disoriented","distracted","distraught","distressed","distrustful","divulge","document","dollar","dominate","doomed","double","doubtful","download","dreadful","dreamy","drive","drowning","dumb","dynamic","eager","earnest","easily","easy","economical","ecstatic","edge","effective","efficient","effortless","elated","eliminate","elite","embarrass","embarrassed","embarrassing","emergency","emerging","emphasize","empowered","enchant","encouraged","endorsed","energetic","energy","enormous","enraged","enthusiastic","envy","epic","epidemic","essential","ethical","euphoric","evil","exactly","exasperated","excellent","excited","excitement","exciting","exclusive","exclusivity","excruciating","exhilarated","expensive","expert","explode","exploit","explosive","exposed","exquisite","extra","extraordinary","extremely","exuberant","eye-opening","fail","fail-proof","failure","faith","famous","fantasy","fascinating","fatigued","faux","faux pas","fearless","feast","feeble","festive","fide","fierce","fight","final","fine","fired","first","first ever","flirt","fluid","focus","focused","fool","fooled","foolish","forbidden","force-fed","forever","forgiving","forgotten","formula","fortune","foul","frantic","free","freebie","freedom","frenzied","frenzy","frightening","frisky","frugal","frustrated","fulfill","fulfilled","full","fully","fun","fun-loving","fundamentals","funniest","funny","furious","gambling","gargantuan","genius","genuine","gift","gigantic","giveaway","glamorous","gleeful","glorious","glowing","goddamn","gorgeous","graceful","grateful","gratified","gravity","great","greatest","greatness","greed","greedy","gripping","grit","grounded","growth","guaranteed","guilt","guilt-free","gullible","guts","hack","happiness","happy","harmful","harsh","hate","have you heard","havoc","hazardous","healthy","heart","heartbreaking","heartwarming","heavenly","hell","helpful","helplessness","hero","hesitant","hidden","high tech","highest","highly effective","hilarious","hoak","hoax","honest","honored","hope","hopeful","horribly","horrific","horrifying","horror","hostile","how to","huge","humility","humor","hurricane","hurry","hypnotic","idiot","ignite","illegal","illusive","imagination","immediately","imminently","impatience","impatient","impenetrable","important","impressive","improved","in the zone","incapable","incapacitated","incompetent","inconsiderate","increase","incredible","indecisive","indulgence","indulgent","inexpensive","inferior","informative","infuriated","ingredients","innocent","innovative","insane","insecure","insider","insidious","inspired","inspiring","instant savings","instantly","instructive","insult","intel","intelligent","intense","interesting","intriguing","introducing","invasion","investment","iron-clad","ironclad","irresistible","irs","is here","jackpot","jail","jaw-dropping","jealous","jeopardy","jittery","jovial","joyous","jubilant","judgmental","jumpstart","just arrived","keen","kickass","kickstart","kill","killed","killing","kills","know it all","lame","largest","lascivious","last","last chance","last minute","latest","laugh","laughing","launch","launching","lavishly","lawsuit","lazy","left behind","legendary","legitimate","liberal","liberated","lick","lies","life-changing","lifetime","light","lighthearted","likely","limited","literally","little-known","loathsome","lonely","looming","loser","lost","love","lucrative","lunatic","lurking","lust","luxurious","luxury","lying","magic","magical","magnificent","mainstream","malicious","mammoth","manipulative","marked down","massive","master","masterclass","maul","mediocre","meditative","meltdown","memorability","memorable","menacing","mesmerizing","meticulous","mind-blowing","minimalist","miracle","mired","mischievous","misgiving","missing out","mistake","monetize","money","moneyback","moneygrubbing","monumental","most important","motivated","mouth-watering","murder","mystery","nail","naked","natural","naughty","nazi","nest egg","never","new","nightmare","no good","no obligation","no one talks about","no questions asked","no risk","no strings attached","non-controlling","noted","novelty","now","obnoxious","obsessed","obsession","obvious","odd","off-kilter","off-limits","off-the record","offensive","official","okay","on-demand","open-minded","opportunities","optimistic","ordeal","outlawed","outrageousness","outstanding","overcome","overjoyed","overnight","overwhelmed","packed","painful","painless","painstaking","pale","panic","panicked","paralyzed","pas","passionate","pathetic","pay zero","payback","perfect","peril","perplexed","perspective","pessimistic","pioneering","piranha","pitfall","pitiful","placid","plague","played","playful","pleased","pluck","plummet","plunge","poison","poisonous","polarizing","poor","popular","portfolio","pound","powerful","powerless","practical","preposterous","prestige","price","priceless","pride","prison","privacy","private","privileged","prize","problem","productive","professional","profit","profitable","profound","promiscuous","promising","promote","protect","protected","proven","provocative","provoke","psychological","pummel","punch","punish","pus","quadruple","quality","quarrelsome","quick","quick-start","quickly","quiet","radiant","rare","ravenous","rebellious","recession-proof","reckoning","recognized","recommend","recreate","reduced","reflective","refugee","refund","refundable","reject","relaxed","release","relentless","reliable","remarkable","replicate","report","reprimanding","repulsed","repulsive","research","resentful","resourceful","responsible","responsive","rested","restricted","results","retaliating","reveal","revealing","revenge","revengeful","revisited","revolting","revolutionary","reward","rich","ridiculous","risky","riveting","rookie","rowdy","ruin","rules","ruthless","sabotaging","sacred","sadistic","sadly","sadness","safe","safety","sale","sampler","sarcastic","satisfied","savage","savagery","save","savings","savvy","scam","scandal","scandalous","scarce","scared","scary","scornful","scream","searing","secret","secret agenda","secret plot","secrets","secure","security","seductive","seething","seize","selected","self-hating","self-sufficient","sensational","senseless","sensual","serene","seriously","severe","sex","sexy","shaking","shameful","shameless","shaming","shatter","shellacking","shocking","should","shrewd","sick and tired","signs","silly","simple","simplicity","simplified","simplistic","sincere","sinful","sins","six-figure","sizable","sizzle","sizzled","sizzles","sizzling","sizzlingly","skill","skyrocket","slaughter","slave","sleazy","sleeping","sly","smash","smiling","smug","smuggle","smuggled","sneak-peek","sneaky","sniveling","snob","snooty","snotty","soar","soaring","solid","solution","spank","special","spectacular","speedy","spell-binding","spine","spirit","spirited","spiteful","spoiler","spontaneous","spotlight","spunky","squirming","stable","staggering","startling","steady","steal","stealthy","steamy","step-by-step","still","stoic","stop","strange","strangle","strategy","stressed","strong","strongly suggest","struggle","stuck up","studies","stunning","stupid","stupid-simple","sturdy","sublime","succeed","success","successful","suck","suddenly","suffer","sunny","super","super-human","superb","supercharge","superior","supported","supportive","sure","sure fire","surefire","surge","surging","surprise","surprised","surprising","survival","survive","suspicious","sweaty","swoon","swoon-worthy","tailspin","tank","tantalizing","targeted","tawdry","tease","technology","teetering","tempting","tenacious","tense","terrible","terrific","terrified","terrifying","terror","terrorist","tested","thankful","the truth","threaten","threatened","thrilled","thrilling","thug","ticked off","tickled","timely","today","torture","toxic","track record","trade secret","tragedy","tragic","transform","transparency","trap","trapped","trauma","traumatized","treacherous","treasure","tremendous","trend","tricks","triggers","triple","triumph","truly","trusting","trustworthy","truth","truthful","turbo-charge","turbocharges","tweaks","twitching","ultimate","unadulterated","unassuming","unauthorized","unbelievable","unburdened","uncaring","uncensored","uncertain","uncomfortable","unconditional","uncontrollable","unconventional","uncovered","undeniable","under priced","undercover","underground","underhanded","underused","unexpected","unforgettable","unheard of","unhurried","uninterested","unique","unjustified","unknowingly","unleashed","unlimited","unlock","unparalleled","unpopular","unreliable","unresponsive","unseen","unstable","unstoppable","unsure","unsurpassed","untapped","unusual","up-sell","upbeat","uplifted","uplifting","urge","urgent","useful","useless","validate","valor","valuable","value","vanquish","vaporize","venomous","verify","vibrant","vicious","victim","victory","vigorous","vilified","vindictive","violated","violent","volatile","vulnerable","waiting","wanted","wanton","warning","waste","weak","wealth","weird","what no one tells you","whip","whopping","wicked","wild","willpower","withheld","wonderful","wondrous","woozy","world","worry","worst","worthwhile","wounded","wreaking","youthful","zen","zinger"],"diacritics":{"A":"[\\u0041\\u24B6\\uFF21\\u00C0\\u00C1\\u00C2\\u1EA6\\u1EA4\\u1EAA\\u1EA8\\u00C3\\u0100\\u0102\\u1EB0\\u1EAE\\u1EB4\\u1EB2\\u0226\\u01E0\\u00C4\\u01DE\\u1EA2\\u00C5\\u01FA\\u01CD\\u0200\\u0202\\u1EA0\\u1EAC\\u1EB6\\u1E00\\u0104\\u023A\\u2C6F]","AA":"[\\uA732]","AE":"[\\u00C6\\u01FC\\u01E2]","AO":"[\\uA734]","AU":"[\\uA736]","AV":"[\\uA738\\uA73A]","AY":"[\\uA73C]","B":"[\\u0042\\u24B7\\uFF22\\u1E02\\u1E04\\u1E06\\u0243\\u0182\\u0181]","C":"[\\u0043\\u24B8\\uFF23\\u0106\\u0108\\u010A\\u010C\\u00C7\\u1E08\\u0187\\u023B\\uA73E]","D":"[\\u0044\\u24B9\\uFF24\\u1E0A\\u010E\\u1E0C\\u1E10\\u1E12\\u1E0E\\u0110\\u018B\\u018A\\u0189\\uA779]","DZ":"[\\u01F1\\u01C4]","Dz":"[\\u01F2\\u01C5]","E":"[\\u0045\\u24BA\\uFF25\\u00C8\\u00C9\\u00CA\\u1EC0\\u1EBE\\u1EC4\\u1EC2\\u1EBC\\u0112\\u1E14\\u1E16\\u0114\\u0116\\u00CB\\u1EBA\\u011A\\u0204\\u0206\\u1EB8\\u1EC6\\u0228\\u1E1C\\u0118\\u1E18\\u1E1A\\u0190\\u018E]","F":"[\\u0046\\u24BB\\uFF26\\u1E1E\\u0191\\uA77B]","G":"[\\u0047\\u24BC\\uFF27\\u01F4\\u011C\\u1E20\\u011E\\u0120\\u01E6\\u0122\\u01E4\\u0193\\uA7A0\\uA77D\\uA77E]","H":"[\\u0048\\u24BD\\uFF28\\u0124\\u1E22\\u1E26\\u021E\\u1E24\\u1E28\\u1E2A\\u0126\\u2C67\\u2C75\\uA78D]","I":"[\\u0049\\u24BE\\uFF29\\u00CC\\u00CD\\u00CE\\u0128\\u012A\\u012C\\u0130\\u00CF\\u1E2E\\u1EC8\\u01CF\\u0208\\u020A\\u1ECA\\u012E\\u1E2C\\u0197]","J":"[\\u004A\\u24BF\\uFF2A\\u0134\\u0248]","K":"[\\u004B\\u24C0\\uFF2B\\u1E30\\u01E8\\u1E32\\u0136\\u1E34\\u0198\\u2C69\\uA740\\uA742\\uA744\\uA7A2]","L":"[\\u004C\\u24C1\\uFF2C\\u013F\\u0139\\u013D\\u1E36\\u1E38\\u013B\\u1E3C\\u1E3A\\u0141\\u023D\\u2C62\\u2C60\\uA748\\uA746\\uA780]","LJ":"[\\u01C7]","Lj":"[\\u01C8]","M":"[\\u004D\\u24C2\\uFF2D\\u1E3E\\u1E40\\u1E42\\u2C6E\\u019C]","N":"[\\u004E\\u24C3\\uFF2E\\u01F8\\u0143\\u00D1\\u1E44\\u0147\\u1E46\\u0145\\u1E4A\\u1E48\\u0220\\u019D\\uA790\\uA7A4]","NJ":"[\\u01CA]","Nj":"[\\u01CB]","O":"[\\u004F\\u24C4\\uFF2F\\u00D2\\u00D3\\u00D4\\u1ED2\\u1ED0\\u1ED6\\u1ED4\\u00D5\\u1E4C\\u022C\\u1E4E\\u014C\\u1E50\\u1E52\\u014E\\u022E\\u0230\\u00D6\\u022A\\u1ECE\\u0150\\u01D1\\u020C\\u020E\\u01A0\\u1EDC\\u1EDA\\u1EE0\\u1EDE\\u1EE2\\u1ECC\\u1ED8\\u01EA\\u01EC\\u00D8\\u01FE\\u0186\\u019F\\uA74A\\uA74C]","OI":"[\\u01A2]","OO":"[\\uA74E]","OU":"[\\u0222]","P":"[\\u0050\\u24C5\\uFF30\\u1E54\\u1E56\\u01A4\\u2C63\\uA750\\uA752\\uA754]","Q":"[\\u0051\\u24C6\\uFF31\\uA756\\uA758\\u024A]","R":"[\\u0052\\u24C7\\uFF32\\u0154\\u1E58\\u0158\\u0210\\u0212\\u1E5A\\u1E5C\\u0156\\u1E5E\\u024C\\u2C64\\uA75A\\uA7A6\\uA782]","S":"[\\u0053\\u24C8\\uFF33\\u1E9E\\u015A\\u1E64\\u015C\\u1E60\\u0160\\u1E66\\u1E62\\u1E68\\u0218\\u015E\\u2C7E\\uA7A8\\uA784]","T":"[\\u0054\\u24C9\\uFF34\\u1E6A\\u0164\\u1E6C\\u021A\\u0162\\u1E70\\u1E6E\\u0166\\u01AC\\u01AE\\u023E\\uA786]","TZ":"[\\uA728]","U":"[\\u0055\\u24CA\\uFF35\\u00D9\\u00DA\\u00DB\\u0168\\u1E78\\u016A\\u1E7A\\u016C\\u00DC\\u01DB\\u01D7\\u01D5\\u01D9\\u1EE6\\u016E\\u0170\\u01D3\\u0214\\u0216\\u01AF\\u1EEA\\u1EE8\\u1EEE\\u1EEC\\u1EF0\\u1EE4\\u1E72\\u0172\\u1E76\\u1E74\\u0244]","V":"[\\u0056\\u24CB\\uFF36\\u1E7C\\u1E7E\\u01B2\\uA75E\\u0245]","VY":"[\\uA760]","W":"[\\u0057\\u24CC\\uFF37\\u1E80\\u1E82\\u0174\\u1E86\\u1E84\\u1E88\\u2C72]","X":"[\\u0058\\u24CD\\uFF38\\u1E8A\\u1E8C]","Y":"[\\u0059\\u24CE\\uFF39\\u1EF2\\u00DD\\u0176\\u1EF8\\u0232\\u1E8E\\u0178\\u1EF6\\u1EF4\\u01B3\\u024E\\u1EFE]","Z":"[\\u005A\\u24CF\\uFF3A\\u0179\\u1E90\\u017B\\u017D\\u1E92\\u1E94\\u01B5\\u0224\\u2C7F\\u2C6B\\uA762]","a":"[\\u0061\\u24D0\\uFF41\\u1E9A\\u00E0\\u00E1\\u00E2\\u1EA7\\u1EA5\\u1EAB\\u1EA9\\u00E3\\u0101\\u0103\\u1EB1\\u1EAF\\u1EB5\\u1EB3\\u0227\\u01E1\\u00E4\\u01DF\\u1EA3\\u00E5\\u01FB\\u01CE\\u0201\\u0203\\u1EA1\\u1EAD\\u1EB7\\u1E01\\u0105\\u2C65\\u0250]","aa":"[\\uA733]","ae":"[\\u00E6\\u01FD\\u01E3]","ao":"[\\uA735]","au":"[\\uA737]","av":"[\\uA739\\uA73B]","ay":"[\\uA73D]","b":"[\\u0062\\u24D1\\uFF42\\u1E03\\u1E05\\u1E07\\u0180\\u0183\\u0253]","c":"[\\u0063\\u24D2\\uFF43\\u0107\\u0109\\u010B\\u010D\\u00E7\\u1E09\\u0188\\u023C\\uA73F\\u2184]","d":"[\\u0064\\u24D3\\uFF44\\u1E0B\\u010F\\u1E0D\\u1E11\\u1E13\\u1E0F\\u0111\\u018C\\u0256\\u0257\\uA77A]","dz":"[\\u01F3\\u01C6]","e":"[\\u0065\\u24D4\\uFF45\\u00E8\\u00E9\\u00EA\\u1EC1\\u1EBF\\u1EC5\\u1EC3\\u1EBD\\u0113\\u1E15\\u1E17\\u0115\\u0117\\u00EB\\u1EBB\\u011B\\u0205\\u0207\\u1EB9\\u1EC7\\u0229\\u1E1D\\u0119\\u1E19\\u1E1B\\u0247\\u025B\\u01DD]","f":"[\\u0066\\u24D5\\uFF46\\u1E1F\\u0192\\uA77C]","g":"[\\u0067\\u24D6\\uFF47\\u01F5\\u011D\\u1E21\\u011F\\u0121\\u01E7\\u0123\\u01E5\\u0260\\uA7A1\\u1D79\\uA77F]","h":"[\\u0068\\u24D7\\uFF48\\u0125\\u1E23\\u1E27\\u021F\\u1E25\\u1E29\\u1E2B\\u1E96\\u0127\\u2C68\\u2C76\\u0265]","hv":"[\\u0195]","i":"[\\u0069\\u24D8\\uFF49\\u00EC\\u00ED\\u00EE\\u0129\\u012B\\u012D\\u00EF\\u1E2F\\u1EC9\\u01D0\\u0209\\u020B\\u1ECB\\u012F\\u1E2D\\u0268\\u0131]","j":"[\\u006A\\u24D9\\uFF4A\\u0135\\u01F0\\u0249]","k":"[\\u006B\\u24DA\\uFF4B\\u1E31\\u01E9\\u1E33\\u0137\\u1E35\\u0199\\u2C6A\\uA741\\uA743\\uA745\\uA7A3]","l":"[\\u006C\\u24DB\\uFF4C\\u0140\\u013A\\u013E\\u1E37\\u1E39\\u013C\\u1E3D\\u1E3B\\u017F\\u0142\\u019A\\u026B\\u2C61\\uA749\\uA781\\uA747]","lj":"[\\u01C9]","m":"[\\u006D\\u24DC\\uFF4D\\u1E3F\\u1E41\\u1E43\\u0271\\u026F]","n":"[\\u006E\\u24DD\\uFF4E\\u01F9\\u0144\\u00F1\\u1E45\\u0148\\u1E47\\u0146\\u1E4B\\u1E49\\u019E\\u0272\\u0149\\uA791\\uA7A5]","nj":"[\\u01CC]","o":"[\\u006F\\u24DE\\uFF4F\\u00F2\\u00F3\\u00F4\\u1ED3\\u1ED1\\u1ED7\\u1ED5\\u00F5\\u1E4D\\u022D\\u1E4F\\u014D\\u1E51\\u1E53\\u014F\\u022F\\u0231\\u00F6\\u022B\\u1ECF\\u0151\\u01D2\\u020D\\u020F\\u01A1\\u1EDD\\u1EDB\\u1EE1\\u1EDF\\u1EE3\\u1ECD\\u1ED9\\u01EB\\u01ED\\u00F8\\u01FF\\u0254\\uA74B\\uA74D\\u0275]","oi":"[\\u01A3]","ou":"[\\u0223]","oo":"[\\uA74F]","p":"[\\u0070\\u24DF\\uFF50\\u1E55\\u1E57\\u01A5\\u1D7D\\uA751\\uA753\\uA755]","q":"[\\u0071\\u24E0\\uFF51\\u024B\\uA757\\uA759]","r":"[\\u0072\\u24E1\\uFF52\\u0155\\u1E59\\u0159\\u0211\\u0213\\u1E5B\\u1E5D\\u0157\\u1E5F\\u024D\\u027D\\uA75B\\uA7A7\\uA783]","s":"[\\u0073\\u24E2\\uFF53\\u015B\\u1E65\\u015D\\u1E61\\u0161\\u1E67\\u1E63\\u1E69\\u0219\\u015F\\u023F\\uA7A9\\uA785\\u1E9B]","ss":"[\\u00DF]","t":"[\\u0074\\u24E3\\uFF54\\u1E6B\\u1E97\\u0165\\u1E6D\\u021B\\u0163\\u1E71\\u1E6F\\u0167\\u01AD\\u0288\\u2C66\\uA787]","tz":"[\\uA729]","u":"[\\u0075\\u24E4\\uFF55\\u00F9\\u00FA\\u00FB\\u0169\\u1E79\\u016B\\u1E7B\\u016D\\u00FC\\u01DC\\u01D8\\u01D6\\u01DA\\u1EE7\\u016F\\u0171\\u01D4\\u0215\\u0217\\u01B0\\u1EEB\\u1EE9\\u1EEF\\u1EED\\u1EF1\\u1EE5\\u1E73\\u0173\\u1E77\\u1E75\\u0289]","v":"[\\u0076\\u24E5\\uFF56\\u1E7D\\u1E7F\\u028B\\uA75F\\u028C]","vy":"[\\uA761]","w":"[\\u0077\\u24E6\\uFF57\\u1E81\\u1E83\\u0175\\u1E87\\u1E85\\u1E98\\u1E89\\u2C73]","x":"[\\u0078\\u24E7\\uFF58\\u1E8B\\u1E8D]","y":"[\\u0079\\u24E8\\uFF59\\u1EF3\\u00FD\\u0177\\u1EF9\\u0233\\u1E8F\\u00FF\\u1EF7\\u1E99\\u1EF5\\u01B4\\u024F\\u1EFF]","z":"[\\u007A\\u24E9\\uFF5A\\u017A\\u1E91\\u017C\\u017E\\u1E93\\u1E95\\u01B6\\u0225\\u0240\\u2C6C\\uA763]"},"researchesTests":["contentHasTOC","contentHasShortParagraphs","contentHasAssets","keywordInTitle","keywordInMetaDescription","keywordInPermalink","keywordIn10Percent","keywordInContent","keywordInSubheadings","keywordInImageAlt","keywordDensity","keywordNotUsed","lengthContent","lengthPermalink","linksHasInternal","linksHasExternals","linksNotAllExternals","titleStartWithKeyword","titleSentiment","titleHasPowerWords","titleHasNumber","hasContentAI"],"hasRedirection":false,"hasBreadcrumb":true},"homeUrl":"https:\/\/neurologiaclinica.es\/en\/","objectID":16595,"objectType":"post","locale":"en","localeFull":"en_US","overlayImages":{"play":{"name":"Play icon","url":"https:\/\/neurologiaclinica.es\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-play.png","path":"\/home2\/accionla\/public_html\/neurologiaclinica.es\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-play.png","position":"middle_center"},"gif":{"name":"GIF icon","url":"https:\/\/neurologiaclinica.es\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-gif.png","path":"\/home2\/accionla\/public_html\/neurologiaclinica.es\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/icon-gif.png","position":"middle_center"}},"defautOgImage":"https:\/\/accionlab.net\/antiguaclinica\/wp-content\/uploads\/2018\/10\/Logo-Neuro_P2.png","customPermalinks":true,"isUserRegistered":true,"autoSuggestKeywords":true,"connectSiteUrl":"https:\/\/rankmath.com\/auth?site=https%3A%2F%2Fneurologiaclinica.es%2Fen%2F&r=https%3A%2F%2Fneurologiaclinica.es%2Fen%2Fwp-json%2Fwp%2Fv2%2Fpages%2F16595%3Fnonce%3Dc028f0d046","maxTags":5,"trendsIcon":"<svg viewBox=\"0 0 610 610\"><path d=\"M18.85,446,174.32,290.48l58.08,58.08L76.93,504a14.54,14.54,0,0,1-20.55,0L18.83,466.48a14.54,14.54,0,0,1,0-20.55Z\" style=\"fill:#4285f4\"\/><path d=\"M242.65,242.66,377.59,377.6l-47.75,47.75a14.54,14.54,0,0,1-20.55,0L174.37,290.43l47.75-47.75A14.52,14.52,0,0,1,242.65,242.66Z\" style=\"fill:#ea4335\"\/><polygon points=\"319.53 319.53 479.26 159.8 537.34 217.88 377.61 377.62 319.53 319.53\" style=\"fill:#fabb05\"\/><path d=\"M594.26,262.73V118.61h0a16.94,16.94,0,0,0-16.94-16.94H433.2a16.94,16.94,0,0,0-12,28.92L565.34,274.71h0a16.94,16.94,0,0,0,28.92-12Z\" style=\"fill:#34a853\"\/><rect width=\"610\" height=\"610\" style=\"fill:none\"\/><\/svg>","showScore":true,"siteFavIcon":"https:\/\/neurologiaclinica.es\/wp-content\/uploads\/favicon.png","canUser":{"general":false,"advanced":false,"snippet":false,"social":false,"analysis":false,"analytics":false,"content_ai":false},"showKeywordIntent":true,"isPro":false,"is_front_page":false,"trendsUpgradeLink":"https:\/\/rankmath.com\/pricing\/?utm_source=Plugin&utm_medium=CE%20General%20Tab%20Trends&utm_campaign=WP","trendsUpgradeLabel":"Upgrade","trendsPreviewImage":"https:\/\/neurologiaclinica.es\/wp-content\/plugins\/seo-by-rank-math\/assets\/admin\/img\/trends-preview.jpg","currentEditor":false,"homepageData":{"assessor":{"powerWords":["a cut above","absolute","absolutely","absolutely lowest","absurd","abuse","accurate","accuse","achieve","actionable","adaptable","adequate","admit","adorable","advantage","advice","affordable","aggravate","aggressive","agitated","agonizing","agony","alarmed","alarming","alienated","aligned","alive","all-inclusive","alluring","always","amazing","amp","animated","annihilate","announcing","anonymous","antagonistic","anxious","apocalypse","appalled","approved","approving","argumentative","armageddon","arrogant","ass kicking","assault","assured","astonishing","astounded","astounding","at ease","atrocious","attack","attractive","audacity","authentic","authoritative","authority","avoid","aware","awe-inspiring","awesome","awkward","backbone","backdoor","backed","backlash","backstabbing","badass","balanced","banned","bargain","barrage","basic","battle","beaming","beat down","beating","beautiful","beauty","begging","behind the scenes","belief","belong","best","best-selling","better","beware","big","billion","black market","blacklisted","blast","blessed","blinded","blissful","blood","bloodbath","bloodcurdling","bloody","blunder","blushing","bold","bomb","bona","bona fide","bonanza","bonus","bootleg","bottom line","bountiful","brave","bravery","brazen","break","breaking","breakthrough","breathtaking","bright","brilliant","broke","brutal","budget","buffoon","bullshit","bully","bumbling","buy","cadaver","calm","cancel anytime","capable","captivate","captivating","carefree","case study","cash","cataclysmic","catapult","catastrophe","caution","censored","centered","certain","certainly","certified","challenge","charming","cheap","cheat","cheat-sheet","cheer","cheerful","child-like","clarity","classified","clear","clueless","collapse","colorful","colossal","comfortable","compare","competitive","complete","completely","completeness","comprehensive","compromise","compulsive","concealed","conclusive","condemning","condescending","confess","confession","confessions","confident","confidential","conquer","conscientious","constructive","content","contrary","controlling","controversial","convenient","convert","cool","cooperative","copy","corpse","corrupt","corrupting","courage","courageous","cover-up","covert","coward","cowardly","crammed","crave","crazy","create","creative","cringeworthy","cripple","crisis","critical","crooked","crush","crushing","damaging","danger","dangerous","daring","dazzling","dead","deadline","deadly","death","decadent","deceived","deceptive","deep","defiance","definitely","definitive","defying","dejected","delicious","delight","delighted","delightful","delirious","delivered","demoralizing","deplorable","depraved","desire","desperate","despicable","destiny","destroy","detailed","devastating","devoted","diagnosed","direct","dirty","disadvantages","disastrous","discount","discover","disdainful","disempowered","disgusted","disgusting","dishonest","disillusioned","disoriented","distracted","distraught","distressed","distrustful","divulge","document","dollar","dominate","doomed","double","doubtful","download","dreadful","dreamy","drive","drowning","dumb","dynamic","eager","earnest","easily","easy","economical","ecstatic","edge","effective","efficient","effortless","elated","eliminate","elite","embarrass","embarrassed","embarrassing","emergency","emerging","emphasize","empowered","enchant","encouraged","endorsed","energetic","energy","enormous","enraged","enthusiastic","envy","epic","epidemic","essential","ethical","euphoric","evil","exactly","exasperated","excellent","excited","excitement","exciting","exclusive","exclusivity","excruciating","exhilarated","expensive","expert","explode","exploit","explosive","exposed","exquisite","extra","extraordinary","extremely","exuberant","eye-opening","fail","fail-proof","failure","faith","famous","fantasy","fascinating","fatigued","faux","faux pas","fearless","feast","feeble","festive","fide","fierce","fight","final","fine","fired","first","first ever","flirt","fluid","focus","focused","fool","fooled","foolish","forbidden","force-fed","forever","forgiving","forgotten","formula","fortune","foul","frantic","free","freebie","freedom","frenzied","frenzy","frightening","frisky","frugal","frustrated","fulfill","fulfilled","full","fully","fun","fun-loving","fundamentals","funniest","funny","furious","gambling","gargantuan","genius","genuine","gift","gigantic","giveaway","glamorous","gleeful","glorious","glowing","goddamn","gorgeous","graceful","grateful","gratified","gravity","great","greatest","greatness","greed","greedy","gripping","grit","grounded","growth","guaranteed","guilt","guilt-free","gullible","guts","hack","happiness","happy","harmful","harsh","hate","have you heard","havoc","hazardous","healthy","heart","heartbreaking","heartwarming","heavenly","hell","helpful","helplessness","hero","hesitant","hidden","high tech","highest","highly effective","hilarious","hoak","hoax","honest","honored","hope","hopeful","horribly","horrific","horrifying","horror","hostile","how to","huge","humility","humor","hurricane","hurry","hypnotic","idiot","ignite","illegal","illusive","imagination","immediately","imminently","impatience","impatient","impenetrable","important","impressive","improved","in the zone","incapable","incapacitated","incompetent","inconsiderate","increase","incredible","indecisive","indulgence","indulgent","inexpensive","inferior","informative","infuriated","ingredients","innocent","innovative","insane","insecure","insider","insidious","inspired","inspiring","instant savings","instantly","instructive","insult","intel","intelligent","intense","interesting","intriguing","introducing","invasion","investment","iron-clad","ironclad","irresistible","irs","is here","jackpot","jail","jaw-dropping","jealous","jeopardy","jittery","jovial","joyous","jubilant","judgmental","jumpstart","just arrived","keen","kickass","kickstart","kill","killed","killing","kills","know it all","lame","largest","lascivious","last","last chance","last minute","latest","laugh","laughing","launch","launching","lavishly","lawsuit","lazy","left behind","legendary","legitimate","liberal","liberated","lick","lies","life-changing","lifetime","light","lighthearted","likely","limited","literally","little-known","loathsome","lonely","looming","loser","lost","love","lucrative","lunatic","lurking","lust","luxurious","luxury","lying","magic","magical","magnificent","mainstream","malicious","mammoth","manipulative","marked down","massive","master","masterclass","maul","mediocre","meditative","meltdown","memorability","memorable","menacing","mesmerizing","meticulous","mind-blowing","minimalist","miracle","mired","mischievous","misgiving","missing out","mistake","monetize","money","moneyback","moneygrubbing","monumental","most important","motivated","mouth-watering","murder","mystery","nail","naked","natural","naughty","nazi","nest egg","never","new","nightmare","no good","no obligation","no one talks about","no questions asked","no risk","no strings attached","non-controlling","noted","novelty","now","obnoxious","obsessed","obsession","obvious","odd","off-kilter","off-limits","off-the record","offensive","official","okay","on-demand","open-minded","opportunities","optimistic","ordeal","outlawed","outrageousness","outstanding","overcome","overjoyed","overnight","overwhelmed","packed","painful","painless","painstaking","pale","panic","panicked","paralyzed","pas","passionate","pathetic","pay zero","payback","perfect","peril","perplexed","perspective","pessimistic","pioneering","piranha","pitfall","pitiful","placid","plague","played","playful","pleased","pluck","plummet","plunge","poison","poisonous","polarizing","poor","popular","portfolio","pound","powerful","powerless","practical","preposterous","prestige","price","priceless","pride","prison","privacy","private","privileged","prize","problem","productive","professional","profit","profitable","profound","promiscuous","promising","promote","protect","protected","proven","provocative","provoke","psychological","pummel","punch","punish","pus","quadruple","quality","quarrelsome","quick","quick-start","quickly","quiet","radiant","rare","ravenous","rebellious","recession-proof","reckoning","recognized","recommend","recreate","reduced","reflective","refugee","refund","refundable","reject","relaxed","release","relentless","reliable","remarkable","replicate","report","reprimanding","repulsed","repulsive","research","resentful","resourceful","responsible","responsive","rested","restricted","results","retaliating","reveal","revealing","revenge","revengeful","revisited","revolting","revolutionary","reward","rich","ridiculous","risky","riveting","rookie","rowdy","ruin","rules","ruthless","sabotaging","sacred","sadistic","sadly","sadness","safe","safety","sale","sampler","sarcastic","satisfied","savage","savagery","save","savings","savvy","scam","scandal","scandalous","scarce","scared","scary","scornful","scream","searing","secret","secret agenda","secret plot","secrets","secure","security","seductive","seething","seize","selected","self-hating","self-sufficient","sensational","senseless","sensual","serene","seriously","severe","sex","sexy","shaking","shameful","shameless","shaming","shatter","shellacking","shocking","should","shrewd","sick and tired","signs","silly","simple","simplicity","simplified","simplistic","sincere","sinful","sins","six-figure","sizable","sizzle","sizzled","sizzles","sizzling","sizzlingly","skill","skyrocket","slaughter","slave","sleazy","sleeping","sly","smash","smiling","smug","smuggle","smuggled","sneak-peek","sneaky","sniveling","snob","snooty","snotty","soar","soaring","solid","solution","spank","special","spectacular","speedy","spell-binding","spine","spirit","spirited","spiteful","spoiler","spontaneous","spotlight","spunky","squirming","stable","staggering","startling","steady","steal","stealthy","steamy","step-by-step","still","stoic","stop","strange","strangle","strategy","stressed","strong","strongly suggest","struggle","stuck up","studies","stunning","stupid","stupid-simple","sturdy","sublime","succeed","success","successful","suck","suddenly","suffer","sunny","super","super-human","superb","supercharge","superior","supported","supportive","sure","sure fire","surefire","surge","surging","surprise","surprised","surprising","survival","survive","suspicious","sweaty","swoon","swoon-worthy","tailspin","tank","tantalizing","targeted","tawdry","tease","technology","teetering","tempting","tenacious","tense","terrible","terrific","terrified","terrifying","terror","terrorist","tested","thankful","the truth","threaten","threatened","thrilled","thrilling","thug","ticked off","tickled","timely","today","torture","toxic","track record","trade secret","tragedy","tragic","transform","transparency","trap","trapped","trauma","traumatized","treacherous","treasure","tremendous","trend","tricks","triggers","triple","triumph","truly","trusting","trustworthy","truth","truthful","turbo-charge","turbocharges","tweaks","twitching","ultimate","unadulterated","unassuming","unauthorized","unbelievable","unburdened","uncaring","uncensored","uncertain","uncomfortable","unconditional","uncontrollable","unconventional","uncovered","undeniable","under priced","undercover","underground","underhanded","underused","unexpected","unforgettable","unheard of","unhurried","uninterested","unique","unjustified","unknowingly","unleashed","unlimited","unlock","unparalleled","unpopular","unreliable","unresponsive","unseen","unstable","unstoppable","unsure","unsurpassed","untapped","unusual","up-sell","upbeat","uplifted","uplifting","urge","urgent","useful","useless","validate","valor","valuable","value","vanquish","vaporize","venomous","verify","vibrant","vicious","victim","victory","vigorous","vilified","vindictive","violated","violent","volatile","vulnerable","waiting","wanted","wanton","warning","waste","weak","wealth","weird","what no one tells you","whip","whopping","wicked","wild","willpower","withheld","wonderful","wondrous","woozy","world","worry","worst","worthwhile","wounded","wreaking","youthful","zen","zinger"],"diacritics":true,"researchesTests":["contentHasTOC","contentHasShortParagraphs","contentHasAssets","keywordInTitle","keywordInMetaDescription","keywordInPermalink","keywordIn10Percent","keywordInContent","keywordInSubheadings","keywordInImageAlt","keywordDensity","keywordNotUsed","lengthContent","lengthPermalink","linksHasInternal","linksHasExternals","linksNotAllExternals","titleStartWithKeyword","titleSentiment","titleHasPowerWords","titleHasNumber","hasContentAI"],"hasBreadcrumb":true,"serpData":{"title":"%sitename% %page% %sep% %sitedesc%","description":"","titleTemplate":"%sitename% %page% %sep% %sitedesc%","descriptionTemplate":"","focusKeywords":"","breadcrumbTitle":"INICIO","robots":{"index":true},"advancedRobots":[],"facebookTitle":"","facebookDescription":"","facebookImage":"","facebookImageID":""}}},"tocTitle":"Table of Contents","tocExcludeHeadings":[],"listStyle":"ul"},"_links":{"self":[{"href":"https:\/\/neurologiaclinica.es\/en\/wp-json\/wp\/v2\/pages\/16595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neurologiaclinica.es\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/neurologiaclinica.es\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/neurologiaclinica.es\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/neurologiaclinica.es\/en\/wp-json\/wp\/v2\/comments?post=16595"}],"version-history":[{"count":1,"href":"https:\/\/neurologiaclinica.es\/en\/wp-json\/wp\/v2\/pages\/16595\/revisions"}],"predecessor-version":[{"id":16596,"href":"https:\/\/neurologiaclinica.es\/en\/wp-json\/wp\/v2\/pages\/16595\/revisions\/16596"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neurologiaclinica.es\/en\/wp-json\/wp\/v2\/media\/16081"}],"wp:attachment":[{"href":"https:\/\/neurologiaclinica.es\/en\/wp-json\/wp\/v2\/media?parent=16595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}